Across the most recent 1 story covering Oxford University — 100% negative sentiment, averaging 7/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance
threshold before it is linked here — a story naming this entity only in passing, as
competitive context for an unrelated subject, does not qualify. That threshold exists
because earlier testing surfaced entity pages cluttered with tangential mentions: a story
about two unrelated companies merging could otherwise populate a third company's page
simply because it was named once for comparison, with no real event of its own. The
timeline below reflects genuine milestones and developments specific to this entity,
cross-referenced against the same source-verification standard applied to every story on
this site. Sentiment measures the directional read of each development for this entity
specifically, not the overall tone of the reporting, and impact weights how consequential
a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and
sentiment are derived.
Timeline
3,000 Cases Milestone
Total cases reach 3,075, with 1,354 deaths, amid healthcare strikes and calls for accelerated countermeasure development.
First Experimental Vaccine Volunteer Dosed
Oxford University reports that the first volunteer group has received its candidate vaccine specifically targeting Bundibugyo.
2,000 Cases Surpassed
Cumulative confirmed cases exceed 2,000, with rapid spread noted in conflict zones.
Outbreak Declared
DR Congo announces its 17th Ebola outbreak, identifying the Bundibugyo strain as the cause.
DRC’s 17th Ebola outbreak has exploded to 3,075 cases and 1,354 deaths, with 1,000 new infections in just 10 days. The Bundibugyo strain has no approved vaccine or treatment, igniting a biotech race: Oxford University has dosed its first volunteer with an experimental vaccine, while other candidates are fast-tracked, creating high-stakes opportunities for pharma developers.
This page surfaces every story mentioning Oxford University across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent
relevance to the story, filtering out passing mentions. According to that methodology,
reviewed July 2026, this follows multi-source corroboration standards recommended by
journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
What you see
What it tells you
Story count
Number of distinct stories where Oxford University was a primary or referenced actor.
Recency clustering
Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distribution
Aggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche links
When the same entity surfaces in our sibling networks, we link to those views to enrich context.